Clinical Trials Logo

Transplant-eligible Patients clinical trials

View clinical trials related to Transplant-eligible Patients.

Filter by:
  • None
  • Page 1

NCT ID: NCT00439465 Completed - Myeloma Clinical Trials

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the administration of highly effective "killer" cells (cytotoxic T cells), along with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients. The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer "killer" cells, combined with the administration of IL-2 and GM-CSF.